How a Chinese firm jumped to the front of the virus vaccine race
In May, CanSino became the first globally to publish a full scientific study on its early human trials, an important step because it allows researchers worldwide to assess a vaccine’s potential.
.png)
No hay comentarios:
Publicar un comentario